BioNTech aims to have multiple commercialised cancer drugs by 2030 as it pivots away from Covid-19 vaccines.
Speaking at the J.P. Morgan Healthcare Conference in San Francisco, held Jan. 12–15, BioNTech CEO Ugur Sahin said the company’s “ambition is to build a fully integrated multiproduct oncology company, and 2026 is just the beginning of our road map.”
The Germany-headquartered firm became prominent after co-developing the first mRNA Covid-19 vaccine with Pfizer. With demand for Covid-19 products waning, BioNTech’s share price is trading about 77% below its August 2021 peak. The company will continue producing adaptive Covid-19 vaccines for future infectious seasons but is shifting strategy toward oncology to boost revenues.
BioNTech has more than 25 Phase II and III oncology programmes and 10 novel-combination trials. Its cancer pipeline includes next-generation immunomodulators, antibody drug conjugates (ADCs), and mRNA cancer immunotherapies.
The company is betting on several candidates. Pumitamig, a PD-L1/VEGF bispecific antibody, is positioned as a potential next-generation immune-oncology standard across multiple indications; in June 2025 Bristol Myers Squibb signed a deal worth up to $11 billion to co-develop it. Gotistobart, an anti-CTLA-4 therapy for lung cancer, has shown success in a Phase III trial. Some ADCs are being developed for a pan-tumour strategy, while individualized mRNA vaccines are in trials for pancreatic, bladder, and colorectal cancers. BioNTech strengthened its mRNA capabilities with a $1.25 billion acquisition of CureVac in June 2025.
Citi analysts praised the late-stage data flow, saying: “We continue to like the cadence and quality of data coming from the late-stage pipeline and see the company as a differentiated play among traditional vaccine names as it continues its transformation into a commercial oncology company, which should serve to more than offset downsides from vaccine volatility.”
Pumitamig is one of five late-stage readouts expected in 2026 as BioNTech enters a data-heavy period. The company is also building its commercial framework ahead of potential approvals. Sahin said the firm is “entering a phase of sustained clinical data output from 2026 to 2029” and is developing indication-specific expertise and market access capabilities for anticipated first launches.
“For 2030, we expect that BioNTech will be a diversified multiproduct technology company,” Sahin added.
In November, BioNTech raised its 2025 revenue guidance and ended the year with more than $17 billion in cash, cash equivalents and securities. CFO Ramón Zapata-Gomez said the company will prioritize investing in its internal pipeline while leaving open acquisitions and collaborations as secondary uses of capital.
Leave a Reply